AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $517,505 | -14.8% | 42,558 | -12.0% | 0.00% | -50.0% |
| Q2 2023 | $607,100 | +0.8% | 48,336 | -11.0% | 0.00% | 0.0% |
| Q1 2023 | $602,553 | +52.4% | 54,333 | +67.8% | 0.00% | +100.0% |
| Q4 2022 | $395,396 | -92.0% | 32,383 | -93.2% | 0.00% | -94.1% |
| Q3 2022 | $4,958,000 | +27.4% | 474,904 | +31.1% | 0.02% | +30.8% |
| Q2 2022 | $3,891,000 | -7.3% | 362,283 | -18.2% | 0.01% | +8.3% |
| Q1 2022 | $4,196,000 | -77.7% | 443,083 | -72.8% | 0.01% | -70.0% |
| Q4 2021 | $18,817,000 | +77.5% | 1,629,190 | +46.8% | 0.04% | +66.7% |
| Q3 2021 | $10,600,000 | +74.7% | 1,109,969 | +76.3% | 0.02% | +71.4% |
| Q2 2021 | $6,069,000 | -73.9% | 629,581 | -73.3% | 0.01% | -77.0% |
| Q1 2021 | $23,258,000 | -28.1% | 2,354,088 | +68.1% | 0.06% | -34.4% |
| Q4 2020 | $32,344,000 | +212.7% | 1,400,793 | +91.2% | 0.09% | +151.4% |
| Q3 2020 | $10,343,000 | +30.6% | 732,513 | +39.4% | 0.04% | -5.1% |
| Q2 2020 | $7,922,000 | +890.2% | 525,318 | +506.6% | 0.04% | +457.1% |
| Q1 2020 | $800,000 | -87.1% | 86,607 | -86.4% | 0.01% | -63.2% |
| Q4 2019 | $6,218,000 | +55.4% | 638,432 | +28.0% | 0.02% | +46.2% |
| Q3 2019 | $4,000,000 | +140.2% | 498,747 | +273.8% | 0.01% | +116.7% |
| Q2 2019 | $1,665,000 | +71.6% | 133,416 | +87.0% | 0.01% | +100.0% |
| Q1 2019 | $970,000 | +198.5% | 71,330 | +165.7% | 0.00% | +200.0% |
| Q3 2018 | $325,000 | +87.9% | 26,845 | +133.3% | 0.00% | 0.0% |
| Q1 2018 | $173,000 | -96.4% | 11,508 | -96.6% | 0.00% | -93.8% |
| Q4 2017 | $4,849,000 | +23.7% | 336,940 | +29.6% | 0.02% | +14.3% |
| Q3 2017 | $3,919,000 | +10.2% | 259,891 | -39.2% | 0.01% | -30.0% |
| Q4 2014 | $3,557,000 | +23.5% | 427,502 | -11.7% | 0.02% | +53.8% |
| Q3 2014 | $2,880,000 | +1061.3% | 484,065 | +550.8% | 0.01% | +1200.0% |
| Q2 2014 | $248,000 | +134.0% | 74,382 | +44.9% | 0.00% | 0.0% |
| Q1 2014 | $106,000 | +140.9% | 51,345 | +173.7% | 0.00% | – |
| Q4 2013 | $44,000 | – | 18,758 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |